RIGL FY 2019 Earnings — Rigel Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RIGLRigel Pharmaceuticals, Inc.

$517M

FY 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$59M+33.2% YoY

Gross Profit

$58M98.5% margin

Operating Income

-$69M-116.5% margin

Net Income

-$67M-112.2% margin

EPS (Diluted)

$-4.00

Cash Flow

Operating Cash Flow

-$42M

Free Cash Flow

-$43M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$148M

Total Liabilities

$94M

Stockholders' Equity

$54M

Cash & Equivalents

$23M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$59M	$45M	+33.2%
Gross Profit	$58M	$44M	+32.0%
Operating Income	-$69M	-$73M	+4.9%
Net Income	-$67M	-$70M	+5.6%